Relationship between sRAGE and hsCRP as Markers of Cardiovascular Disease Risk Factors in Diabetic and Non-Diabetic Men with Central Obesity

Rambu Beppy Hamuaty, Indriyanti Rafi Sukmawati, Ferry Sandra


Background: Interaction between advanced glycation end product (AGE) and receptor for AGE (RAGE) triggers the escalation of inflammatory cytokine expressions. High-sensitivity C-reactive protein (hsCRP), an important inflammatory marker, has been reported to be modulated by soluble RAGE (sRAGE). However, the relationship between hsCRP and sRAGE in diabetes was not clearly described. Therefore present study was conducted to determine the relationship between sRAGE with hsCRP in men with central obese diabetic and non-diabetic. 

Materials and Methods: Adult men aged 25-60 years with central obese diabetes and non-diabetes, were recruited. Patient’s profiles were collected before the physical and blood examination. Physical examinations were conducted by measuring waist/abdomen, blood pressure, height, and weight. The routine blood test was performed to obtain concentrations of fasting blood glucose, HbA1c, hsCRP and sRAGE level.

Results: Fifty-seven subjects with central obese and waist size ≥90 cm were selected. It was found that hsCRP values were significantly different (p=0.000) in HbA1c <6.5% dan HbA1c ≥6.5% groups. There was an inverse relationship between hsCRP and sRAGE levels for both in HbA1c <6.5% (r=-0.073) and HbA1c≥6.5% (r=-0.022) groups. In HbA1c ≥6.5% group, sRAGE showed strong positive correlation with 1 mg/dL ≤ hsCRP <3 mg/dL group (r>0.5).

Conclusions: In the early stages of diabetes with hsCRP <1 mg/dL, the protective function was demonstrated with greater sRAGE levels. However, in further phase with 3 ≤ hsCRP < 10 mg/dL, the level of sRAGE was low, which is assumed to be associated with complications. Hence, sRAGE could be suggested as a complementary marker for hsCRP to evaluate diabetic men with central obesity.

Keywords: sRAGE, hsCRP, diabetes, HbA1c, central obesity

Full Text:



Rachmi CN, Li M, Alison Baur L. Overweight and Obesity in Indonesia: Prevalence and Risk Factors - A Literature Review. Public Health. 2017; 147: 20-9. CrossRef

Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006; 444(7121): 860-7. CrossRef

Dandona P, Aljada A, Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol. 2004; 25(1): 4-7. CrossRef

Daulay DY, As'ad S, Mappahya AA, Wijaya A. Concentration of endogenous secretory receptor for advanced glycation end products and matrix Gla protein in controlled and uncontrolled type 2 diabetes mellitus patients. Indones Biomed J. 2013; 5(1): 31-6. CrossRef

Koyama H, Shoji T, Hisayo K. Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol. 2005; 25(12): 2587-93. CrossRef

Yamamoto Y, Yamamoto H. RAGE-mediated inflammation, type 2 diabetes, and diabetic vascular complication. Front Endocrinol (Lausanne). 2013; 4: 105. doi: 10.3389/fendo.2013.00105. CrossRef

Hudson BI, Harja E, Moser B, Schmidt AM. Soluble levels of receptor for advanced glycation endproducts (sRAGE) and coronary artery disease: the next C-reactive protein?. Arterioscler Thromb Vasc Biol. 2005; 25(5): 879-82. CrossRef

Emanuele E, D’Angelo S, Tomaino C, Binetti G, Ghidoni R, Politi P, et al. Circulating levels of advanced glycation end products in alzheimer disease and vascular dementia. Arch Neurol. 2005; 62(11): 1734-6. CrossRef

Todingrante A, Arief M, Bahrun U, Sandra F. Study of low-grade chronic inflammatory markers in men with central obesity: cathepsin S was correlated with waist circumference. Indones Biomed J. 2013; 5(2): 115-20. CrossRef

Ritawaty, Sukmawati IR, Patellongi I, Sandra F. Pathomechanism of insulin resistance in men with central obesity: correlation of GGT, GPx, hs-CRP and plasma total cysteine. Indones Biomed J. 2013; 5(2): 101-6. CrossRef

Sargowo D, Sandra F. Combination of Fibrinogen and High-sensitivity C-reactive Protein Measurements is Potential in Identification of Acute Coronary Syndrome. Indones Biomed J. 2015; 7(1): 31-6. CrossRef

An XF, Zhao Y, Yu JY, Liu JS, Gu WJ, Gao F. Plasma sRAGE is independently associated with high sensitivity C-reacive protein in type 2 diabetes without coronary artery disease. Diabetes Res Clin Pract. 2010; 87(3): e19-22. CrossRef

McNair ED, Wells CR, Mabood Qureshi A, Basran R, Pearce C, Orvold J, et al. Modulation of high sensitivity C-reactive protein by soluble receptor for advanced glycation end products. Mol Cell Biochem. 2010; 341(1-2): 135-8. CrossRef

Basta G, Del Turco S, Navarra T, Mazzarisi A, Cocci F, Coceani M, et al. Inverse association between circulating levels of soluble receptor for advanced glycation end-products and coronary plaque burden. J Atheroscler Thromb. 2012; 19(10): 941-8. CrossRef

Vazzana N, Santilli F, Cuccurullo C, Davi G. Soluble forms of RAGE in internal medicine. Intern Emerg Med. 2009; 4(5): 389-401. CrossRef

Bucciarelli LG, Wendt T, Qu W, Lu Y, Lalla E, Rong LL, et al. RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation. 2002; 106(22): 2827-35. CrossRef

Ramasamy R, Yan SF, Schmidt AM. The diverse ligand repertoire of the receptor for advanced glycation endproducts & pathways to the complications of diabetes. Vascul Pharmacol. 2012; 57(5-6): 160-7. CrossRef

Schalkwijk CG, Stehouwer CDA. Comment on: Selvin et al. sRAGE and risk of diabetes, cardiovascular disease, and death. Diabetes 2013;62:2116-2121. Diabetes. 2013; 62(10): e25. doi: 10.2337/db13-1031. CrossRef


Copyright (c) 2017 Molecular and Cellular Biomedical Sciences

Indexed by:





Cell and BioPharmaceutical Institute